We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Kontra Investment Xchange’s Substack by ...

The collaboration between the two companies reflects ongoing efforts to enhance drug development, the CEO of Immunai said.

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

JERUSALEM (Reuters) - Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in ...

Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $17.11. Prasad covers the ...

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

The European Commission has fined Teva , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple ...

We expect them to fuel Teva’s business greatly, especially as the company attempts to get Austedo and Uzedy approved in Europe and Asia. These three drugs made up roughly 10% of company's total ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...